IP Library Granted Patent US 7,863,045
Granted Patent B2
US 7,863,045 · App. 12/176,256 · Granted Jan 4, 2011

Isolation of skeletal precursor cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,863,045
App. No.
12/176,256
Granted
Jan 4, 2011
Kind
B2
Abstract

Cartilage-derived morphogenetic protein CDMP-1 or a transforming growth factor β having at least 80% homology with CDMP-1, or a factor co-expressed and/or co-detectable therewith, is used as a marker of skeletal precursor cells from any part of a mammalian body.

Claims (12)

1. A method of identifying viable, expanded or passaged, committed skeletal precursor cells capable of differentiating into skeletal tissues comprising the step of:

detecting the expression of cartilage-derived morphogenic protein-1 (CDMP-1) in an in vitro cell culture of cells obtained from human periosteum, synovial membrane or bone marrow,

wherein the expression of CDMP-1 identifies skeletal precursor cells.

2. The method according to claim 1 , wherein the expression of CDMP-1 is detected at the DNA, mRNA, cDNA or protein level and/or via the activity of a CDMP-1 promoter that is operably linked to a heterologous reporter gene.

3. The method according to claim 1 , wherein the step of detecting CDMP-1 expression includes applying a binding agent for CDMP-1 to the in vitro cell culture.

4. The method according to claim 1 , which further comprises detecting the absence of expression of a marker selected from the group consisting of FGFR3, type II collagen, type IX collagen, type X collagen, type XI collagen, and BMP-2.

5. A method of obtaining a homogenous culture of viable, expanded or passaged, committed skeletal precursor cells capable of differentiating into skeletal tissues comprising the steps of:

a) detecting the expression of cartilage-derived morphogenic protein-1 (CDMP-1) in an in vitro cell culture of cells obtained from human periosteum, synovial membrane or bone marrow; and

b) selecting or enriching CDMP-1 positive cells, thereby producing a homogenous culture of skeletal precursor cells capable of differentiating into skeletal tissue.

6. The method according to claim 5 wherein the expression of CDMP-1 is detected at the DNA, mRNA, cDNA or protein level and/or via the activity of a CDMP-1 promoter that is operably linked to a heterologous reporter gene.

7. The method according to claim 5 , wherein the step of detecting CDMP-1 expression includes applying a binding agent for CDMP-1 to the in vitro cell culture.

8. The method according to claim 5 , which further comprises detecting the absence of expression of a marker selected from the group consisting of FGFR3, type II collagen, type IX collagen, type X collagen, type XI collagen, and BMP-2.

Assignments (2)
SECURITY AGREEMENT Recorded Jan 23, 2014
From: TIGENIX NV
To: KREOS CAPITAL IV (UK) LIMITED
Reel/Frame 032123/0953 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2008
From: LUYTEN, FRANK; DE BARI, COSIMO; DELL'ACCIO, FRANCESCO
To: TIGENIX N.V.
Reel/Frame 021655/0051 →